Molecular Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 12, 2024
Controlled
drug
delivery
technology
has
matured
for
more
than
70
years,
starting
from
a
twice-a-day
oral
formulation
to
6
month
long-acting
injectable
formulations.
Further
technological
advances
require
superior
formulations
treat
various
diseases
efficiently.
Developing
future
with
practical
innovations
treating
existing
and
new
necessitates
our
continued
efforts
overcome
at
least
three
main
hurdles.
They
include
(i)
reduced
side
effects,
(ii)
long-term
treatment
of
chronic
diseases,
(iii)
the
overcoming
biological
barriers.
Such
start
improved
ability
accurately
test
efficacy
using
proper
controls.
Future
development
can
be
aided
by
artificial
intelligence
if
used
properly.
The
next
revolution
systems
will
augmented
implementation
is
given
equal
weight
as
discovery.
process
accelerated
systemic
revamp
research
funding
structure
cultivating
generation
scientists
who
think
differently.
Chemical Society Reviews,
Journal Year:
2024,
Volume and Issue:
53(3), P. 1167 - 1315
Published: Jan. 1, 2024
Silicon-based
biomaterials
have
been
extensively
developed
in
the
past
decades.
The
classification,
characteristics,
multi-dimensional
design,
and
biomedical
applications
of
silicon-containing
are
comprehensively
elaborated.
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
13(20)
Published: April 6, 2024
Abstract
The
development
of
functional
nanoplatforms
to
improve
the
chemotherapy
outcome
and
inhibit
distal
cancer
cell
metastasis
remains
an
extreme
challenge
in
management.
In
this
work,
a
human‐derived
PC‐3
membrane‐camouflaged
chitosan‐polypyrrole
nanogel
(CH‐PPy
NG)
platform,
which
can
be
loaded
with
chemotherapeutic
drug
docetaxel
(DTX)
RANK
siRNA
for
targeted
gene
silencing‐mediated
inhibition
late‐stage
prostate
mouse
model,
is
reported.
prepared
NGs
size
155.8
nm
show
good
biocompatibility,
pH‐responsive
release
profile,
homologous
targeting
specificity
cells,
allowing
efficient
precise
drug/gene
co‐delivery.
Through
in‐vivo
antitumor
treatment
xenografted
tumor
it
shown
that
such
CH‐PPy
NG‐facilitated
co‐delivery
system
allows
effective
slow
down
growth
rate,
effectively
inhibits
bone
via
downregulation
RANK/RANKL
signaling
pathway.
created
CH‐Ppy
may
utilized
as
promising
platform
enhanced
anti‐metastasis
cancer.
ACS Materials Letters,
Journal Year:
2024,
Volume and Issue:
6(2), P. 517 - 527
Published: Jan. 3, 2024
The
development
of
drug
delivery
strategies
with
the
desired
immunomodulation
effects
to
alleviate
tumor
resistance
remains
a
challenge.
Herein,
low-generation
poly(alkylideneamine)
dendrimer
nanogels
(DNGs)
were
developed
codeliver
chemotherapeutics
5-fluorouracil
(5-FU)
and
immune
agonist
cyclic
GMP-AMP
(cGAMP)
for
chemoimmunotherapy.
DNGs
possess
hydrodynamic
size
145.6
nm,
excellent
drug/nucleotide
coloading
capacity,
pH-sensitive
release
profile.
5-FU-loaded
can
overcome
5-FU
through
prolonged
cellular
retention
downregulation
P-glycoprotein
expression
on
cancer
cell
surface.
Meanwhile,
cGAMP
in
codelivery
system
activate
stimulator
interferon
genes
pathway
cells,
which
further
relives
modulates
microenvironment
maturation
dendritic
cells
macrophage
M1
polarization.
immunomodulation-facilitated
alleviation
was
confirmed
vivo
subcutaneous
colorectal
mouse
model,
leading
relatively
long
retention,
inhibition
growth,
generation
active
antitumor
responses.
